AGN193109 is a highly effective antagonist of retinoid action in human ectocervical epithelial cells

被引:72
作者
Agarwal, C
Chandraratna, RAS
Johnson, AT
Rorke, EA
Eckert, RL
机构
[1] CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106
[2] CASE WESTERN RESERVE UNIV,SCH MED,DEPT DERMATOL,CLEVELAND,OH 44106
[3] CASE WESTERN RESERVE UNIV,SCH MED,DEPT REPROD BIOL,CLEVELAND,OH 44106
[4] CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106
[5] CASE WESTERN RESERVE UNIV,SCH MED,DEPT ENVIRONM HLTH SCI,CLEVELAND,OH 44106
[6] ALLERGAN PHARMACEUT INC,DEPT CHEM,RETINOID RES,IRVINE,CA 92713
[7] ALLERGAN PHARMACEUT INC,DEPT BIOL,IRVINE,CA 92713
关键词
D O I
10.1074/jbc.271.21.12209
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Retinoids are important physiological agents that regulate epithelial cell differentiation and proliferation. The importance of these agents in regulating growth, development, and differentiation has led to a search for new retinoid agonists and antagonists. In the present manuscript we show that AGN193109, a retinoid analog, is an efficient antagonist of retinoid action in human cervical epithelial cells. Treatment of ECE16-1 cells with natural or synthetic retinoids reduces cytokeratin K5, K6, K14, K16, and K17 levels, increases cytokeratin K7, K8, and K19 levels, increases retinoic acid receptor-beta (RAR beta) mRNA levels, suppresses proliferation, and alters cell morphology. Co-treatment with AGN193109 prevents these responses. Half-maximal and maximal antagonism is observed at a molar ratio of AGN193109: retinoid agonist of 1:1 and 10:1, respectively. When administered alone AGN193109 has no agonist activity. Thus, AGN193109, which binds to RAR alpha, RAR beta, and RAR gamma with K-d values = 2, 2, and 3 nM, respectively, but is unable to bind to the retinoid X receptors, is a highly active antagonist of retinoid action in ECE16-1 cells.
引用
收藏
页码:12209 / 12212
页数:4
相关论文
共 43 条
  • [1] AGARWAL C, 1994, CANCER RES, V54, P2108
  • [2] Agarwal C, 1996, CELL GROWTH DIFFER, V7, P521
  • [3] AGARWAL C, 1991, CANCER RES, V51, P3982
  • [4] RETINOID-DEPENDENT TRANSCRIPTIONAL SUPPRESSION OF CYTOKERATIN GENE-EXPRESSION IN HUMAN EPIDERMAL SQUAMOUS-CELL CARCINOMA-CELLS
    AGARWAL, C
    RORKE, EA
    BOYCE, M
    HOWARD, J
    CRISH, J
    HUFEISEN, S
    ECKERT, RL
    [J]. DIFFERENTIATION, 1993, 52 (02) : 185 - 191
  • [5] A RETINOIC ACID RECEPTOR-ALPHA ANTAGONIST SELECTIVELY COUNTERACTS RETINOIC ACID EFFECTS
    APFEL, C
    BAUER, F
    CRETTAZ, M
    FORNI, L
    KAMBER, M
    KAUFMANN, F
    LEMOTTE, P
    PIRSON, W
    KLAUS, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (15) : 7129 - 7133
  • [6] SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF STILBENE RETINOID ANALOGS SUBSTITUTED WITH HETEROAROMATIC CARBOXYLIC-ACIDS
    BEARD, RL
    CHANDRARATNA, RAS
    COLON, DF
    GILLETT, SJ
    HENRY, E
    MARLER, DK
    SONG, T
    DENYS, L
    AREFIEG, T
    KLEIN, E
    GIL, DW
    WHEELER, L
    KOCHHAR, DM
    DAVIES, PJA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (15) : 2820 - 2829
  • [7] A NEW RETINOIC ACID RECEPTOR IDENTIFIED FROM A HEPATOCELLULAR-CARCINOMA
    BENBROOK, D
    LERNHARDT, E
    PFAHL, M
    [J]. NATURE, 1988, 333 (6174) : 669 - 672
  • [9] IDENTIFICATION OF A 2ND HUMAN RETINOIC ACID RECEPTOR
    BRAND, N
    PETKOVICH, M
    KRUST, A
    CHAMBON, P
    DETHE, H
    MARCHIO, A
    TIOLLAIS, P
    DEJEAN, A
    [J]. NATURE, 1988, 332 (6167) : 850 - 853
  • [10] SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF CONFORMATIONALLY RESTRICTED, ACETYLENIC RETINOID ANALOGS
    CHANDRARATNA, RAS
    GILLETT, SJ
    SONG, TK
    ATTARD, J
    VULIGONDA, S
    GARST, ME
    AREFIEG, T
    GIL, DW
    WHEELER, L
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1995, 5 (05) : 523 - 527